In HepG2 hepatocellular carcinoma cells, HBXIP activates the PI3/Akt signaling pathway, which upregulates the expression of cyclin-D1 and phosphorylated protein kinase B, and downregulates that of p53 and p21 (35). Here, LAMTOR5 is linked to hepatocellular carcinoma.